NUCB2 and metabolic disease: reported that nesfatin-1 exerts its metabolic effects partly via promoting insulin release by Ca+2 influx through L-Type Ca+2 channels independently of protein kinase A (PKA) and phospholipase A2 (PLA2) so that dysregulation of nesfatin-1 might be implicated in metabolic disorders, particularly in Type 2 DM (16).